TY - JOUR
T1 - Fatigue in inflammatory bowel disease and its impact on daily activities
AU - the Swiss IBD Cohort Study Group
AU - Schreiner, Philipp
AU - Rossel, Jean Benoît
AU - Biedermann, Luc
AU - Valko, Philipp O.
AU - Baumann, Christian R.
AU - Greuter, Thomas
AU - Scharl, Michael
AU - Vavricka, Stephan R.
AU - Pittet, Valérie
AU - Juillerat, Pascal
AU - Rogler, Gerhard
AU - von Känel, Roland
AU - Misselwitz, Benjamin
AU - Abdelrahman, Karim
AU - Ademi, Gentiana
AU - Aepli, Patrick
AU - Thomas, Amman
AU - Anderegg, Claudia
AU - Antonino, Anca Teodora
AU - Archanioti, Eva
AU - Arrigoni, Eviano
AU - Aslan, Nurullah
AU - Bakker de Jong, Diana
AU - Balsiger, Bruno
AU - Bastürk, Polat
AU - Bauerfeind, Peter
AU - Becocci, Andrea
AU - Bengoa, José M.
AU - Biedermann, Luc
AU - Binek, Janek
AU - Blattmann, Mirjam
AU - Boehm, Stephan
AU - Boldanova, Tujana
AU - Borovicka, Jan
AU - Braegger, Christian P.
AU - Brand, Stephan
AU - Bravo, Francisco
AU - Brügger, Lukas
AU - Brunner, Simon
AU - Bühr, Patrick
AU - Burk, Sabine
AU - Burri, Emanuel
AU - Butter, Matthias
AU - Buyse, Sophie
AU - Cao, Dahlia Thao
AU - Carstens, Ove
AU - Criblez, Dominique H.
AU - D’Angelo, Fabrizia
AU - Saussure, Philippe
AU - Sauter, Bernhard
N1 - Publisher Copyright:
© 2020 John Wiley & Sons Ltd
PY - 2021/1
Y1 - 2021/1
N2 - Background: Fatigue is a common symptom of chronic inflammation, including inflammatory bowel disease (IBD), resulting in significant impairment in quality of life. Aims: To identify the prevalence of fatigue in a large IBD cohort compared to the general population, address risk factors, and evaluate its impact on daily life. Methods: We evaluated 1208 IBD patients from the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) and 414 healthy controls. Significant fatigue was defined as a visual analogue scale (VAS-F, range 0-10) score ≥ 4. Secondary endpoints were severity of fatigue and its impact on daily activities with the Fatigue Severity Scale (FSS), with a score ≥ 4 indicative of fatigue. Demographic, IBD-related and psychiatric symptoms were assessed with a multivariate analysis of variance (MANOVA) model optimised for prediction of VAS-F (primary outcome) and FSS scores. Results: Overall, 672 IBD patients (55.6%) reported significant fatigue compared to 145 (35%) controls (OR 2.71; 95% CI 2.08-3.54; P < 0.001). In IBD, fatigue also significantly affected daily activities (FSS ≥ 4; 405 (33.5%) IBD patients vs 81 (19.6%) controls, P < 0.001). In the MANOVA model, fatigue levels were associated with female gender (coefficient 0.839; 0.556 - 1.123; P < 0.001), younger age at diagnosis (−0.031 per year; −0.042– −0.019; P < 0.001), shorter disease duration (−0.036 per year; −0.050– −0.022; P < 0.001), nocturnal diarrhoea (0.718; 0.295-1.141; P = 0.001), low educational level (P = 0.034) and symptoms of depression and anxiety. Conclusions: Fatigue is both more frequent and more severe in patients with IBD than in the general population.
AB - Background: Fatigue is a common symptom of chronic inflammation, including inflammatory bowel disease (IBD), resulting in significant impairment in quality of life. Aims: To identify the prevalence of fatigue in a large IBD cohort compared to the general population, address risk factors, and evaluate its impact on daily life. Methods: We evaluated 1208 IBD patients from the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) and 414 healthy controls. Significant fatigue was defined as a visual analogue scale (VAS-F, range 0-10) score ≥ 4. Secondary endpoints were severity of fatigue and its impact on daily activities with the Fatigue Severity Scale (FSS), with a score ≥ 4 indicative of fatigue. Demographic, IBD-related and psychiatric symptoms were assessed with a multivariate analysis of variance (MANOVA) model optimised for prediction of VAS-F (primary outcome) and FSS scores. Results: Overall, 672 IBD patients (55.6%) reported significant fatigue compared to 145 (35%) controls (OR 2.71; 95% CI 2.08-3.54; P < 0.001). In IBD, fatigue also significantly affected daily activities (FSS ≥ 4; 405 (33.5%) IBD patients vs 81 (19.6%) controls, P < 0.001). In the MANOVA model, fatigue levels were associated with female gender (coefficient 0.839; 0.556 - 1.123; P < 0.001), younger age at diagnosis (−0.031 per year; −0.042– −0.019; P < 0.001), shorter disease duration (−0.036 per year; −0.050– −0.022; P < 0.001), nocturnal diarrhoea (0.718; 0.295-1.141; P = 0.001), low educational level (P = 0.034) and symptoms of depression and anxiety. Conclusions: Fatigue is both more frequent and more severe in patients with IBD than in the general population.
UR - http://www.scopus.com/inward/record.url?scp=85096687358&partnerID=8YFLogxK
U2 - 10.1111/apt.16145
DO - 10.1111/apt.16145
M3 - Article
C2 - 33159475
AN - SCOPUS:85096687358
SN - 0269-2813
VL - 53
SP - 138
EP - 149
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 1
ER -